Latest news with #pharmaceuticals
Yahoo
2 hours ago
- Business
- Yahoo
Cardinal Health (CAH) Beat the Market in 2025 with Solid Healthcare Momentum
Cardinal Health, Inc. (NYSE:CAH) is one of the Best Dividend Stocks of 2025. A senior physician in a modern healthcare institution administering medication to a patient. Cardinal Health, Inc. (NYSE:CAH) has surged by nearly 39% since the start of 2025. The company remains focused on strengthening the growth and stability of its Pharmaceutical and Specialty Solutions segment by expanding its presence in specialty care, advancing high-growth areas, and continuing the execution of its GMPD Improvement Plan. Cardinal Health, Inc. (NYSE:CAH) has also reaffirmed its commitment to investing in Biopharma Solutions. Its Specialty Networks are broadening the reach of their PPS Analytics and SoNaR data platforms, which were initially developed for urology. These platforms are now being extended into oncology, gastroenterology, and rheumatology to better support manufacturing partners and healthcare providers, including physicians connected through Cardinal Health's MSO platforms. On May 6, Cardinal Health, Inc. (NYSE:CAH) declared a 1% hike in its quarterly dividend to $0.5107 per share. Through this increase, the company stretched its dividend growth streak to 39 years. The stock offers a dividend yield of 1.23%, as of June 26. While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
8 hours ago
- Business
- Associated Press
BioNxt Solutions Announces Revocation of Management Cease Trade Order
VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), is pleased to announce that effective immediately, the British Columbia Securities Commission has revoked the temporary management cease trade order ('MCTO') it had previously granted to the Company on May 1, 2025 under National Policy 12-203 Management Cease Trade Orders, as the Company successfully completed the filing of its annual audited financial statements, management's discussion and analysis, and related certifications for the year ended December 31, 2024 (collectively, the 'Annual Filings') on June 26, 2025. The revocation of the MCTO means members of management are no longer prevented from trading the Company's securities. All of the Annual Filings are available under the Company's profile on SEDAR+ at About BioNxt Solutions Inc. BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide. BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit Investor Relations & Media Contact Hugh Rogers, Co‐Founder, CEO and Director Email: [email protected] Phone: +1 778.598.2698 Web: LinkedIn: Instagram: Cautionary Statement Regarding 'Forward‐Looking' Information This news release includes certain statements that may be deemed 'forward-looking statements'. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Forward-looking information in this news release includes the anticipated filing date of the Annual Filings. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. SOURCE: BioNxt Solutions Inc. press release
Yahoo
10 hours ago
- Business
- Yahoo
Incyte replaces CEO Hoppenot with dealmaker Meury
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Incyte has named veteran pharmaceutical executive Bill Meury as its new CEO, replacing longtime head Hervé Hoppenot, who led the cancer and blood disease drugmaker for the past 11 years. Meury, whose appointment is effective immediately, previously ran Anthos Therapeutics, which he sold this year to Novartis for nearly $1 billion, and Karuna Therapeutics, which Bristol Myers Squibb bought for $14 billion in 2023. Prior to those posts, Meury was chief commercial officer at Allergan. Hoppenot will remain on Incyte's board of directors through the end of this year to aid Meury's transition into the CEO role. Alongside the succession, Julian Baker, managing partner of biotechnology investor Baker Bros. Advisors and lead independent director for Incyte, was elected board chair. Much of Hoppenot's time at Incyte focused on what he once described as 'single asset syndrome.' The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. Last year, Jakafi brought in nearly $2.8 billion in sales. But Jakafi's main patents expire in 2028, a date that for years now has been on investors' radar as they've pressed Incyte on what it expects will take the drug's place. Early in Hoppenot's tenure, the answer looked like a cancer medicine called epacadostat, which Incyte believed could become a cornerstone of immunotherapy combinations. However, it flamed out in testing in 2018 and Incyte was forced to pivot research toward other candidates. Since then, Incyte has had some success building out its portfolio. The company now owns six other approved drugs, including a cream formulation of Jakafi's main ingredient that's proved useful treating atopic dermatitis and vitiligo. 'Hervé joined Incyte in 2014 when it was a single product, U.S.-only company,' said board member Baker, in a statement. 'During Hervé's tenure, Incyte launched six novel medicines plus two new indications for Jakafi, expanded commercial operations into Europe, Japan and Canada and grew revenues from $355 million dollars in 2013 to $4.2 billion today.' However, Incyte's other drugs don't make it much money. Jakafi and the cream formulation of the drug Incyte sells as Opzelura accounted for 91% of net product revenues last year. (The company also earned nearly $600 million in royalty revenues.) Stephen Willey, an analyst at Stifel, gives Hoppenot credit for increasing Incyte revenues by more than 10 times during his time as CEO. But, in a Thursday note to clients, he added that some investors grew frustrated with the company's high research and development spending without a clear post-Jakafi plan. Shaping those plans will now fall to Meury, who gained industry visibility by guiding his prior two companies to lucrative acquisitions. 'We expect the immediate reaction from investors will be an expectation that [Incyte] could now become an M&A target, simply because Mr. Meury sold Anthos ... and sold [Karuna],' wrote RBC Capital Markets analyst Brian Abrahams, in a note to clients. Shares in Incyte, which have fallen by 30% over the past five years, rose by more than 4% in Thursday morning trading on the CEO news. 'It has been a privilege to lead Incyte over the past eleven years,' Hoppenot said in the company's statement. 'I am proud to retire at a time when Incyte has the strongest management team, internal R&D pipeline and commercial portfolio ever.' Incyte expects multiple pivotal trial readouts this year, along with proof-of-concept data for several pipeline candidates. Recommended Reading Unblinded: Hervé Hoppenot on solving Incyte's 'single asset syndrome' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Health Line
11 hours ago
- Health
- Health Line
The Cost Breztri of with Medicare
Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) is a metered-dose inhaler designed for adults living with chronic obstructive pulmonary disease (COPD). Medicare might help cover the cost of Breztri for COPD, but it's important to check the specifics of your plan, as there's no nationwide rule for inhaler coverage. Each Medicare Part D or Medicare Advantage Prescription Drug (MAPD) plan may cover different drugs. However, note that if you need a nebulizer rather than an inhaler, you would typically be covered under Medicare Part B. How much does Breztri cost with Medicare? If you don't have insurance, a 5.9-gram (g) Breztri inhaler costs around $400, while a larger 10.7-g inhaler can cost about $700. Whether your Medicare drug plan covers a Breztri inhaler depends on its formulary, which is a list of covered medications that varies with each plan. If your plan's formulary doesn't include this inhaler, it might offer coverage for a different one instead. If your plan covers Breztri, the amount you need to pay depends on its tier within the formulary. Higher tiers usually mean a higher cost. However, starting in 2025, you'll pay no more than $2,000 annually out of pocket for drugs through Medicare plans. Remember, Part D and MAPD plans are managed by private insurance companies, meaning your deductibles, premiums, and copays will depend on your plan. In 2025, the national base beneficiary premium for Part D is $36.78, and according to the Centers for Medicare & Medicaid Services (CMS), the average monthly premium for Medicare Advantage plans is about $17. If you use a nebulizer and have coverage under Part B, you'll pay 20% of the cost after meeting your annual deductible of $257, as long as you keep up with your monthly premium of $185. How can I get cheaper Breztri with Medicare? Typically, you can get cheaper drugs through your Medicare plan by getting a prescription for a generic version. These tend to feature in lower formulary tiers, making them more affordable. There's no generic version of Breztri, but other medications may be just as effective and more budget-friendly. Your Medicare plan may cover these. In fact, since Breztri can be expensive, your plan might require prior authorization before they approve coverage. This could involve step therapy, where you're asked to try a different, equally effective but cheaper medication first. In addition, AstraZeneca, the company that produces Breztri, offers a cost assistance program that may make this drug more affordable for Medicare enrollees. You'll need to visit the manufacturer's website to check your eligibility. Takeaway Breztri is a brand-name inhaler designed for long-term management of chronic obstructive pulmonary disease (COPD) in adults. Although Medicare drug plans may cover COPD inhalers like Breztri, coverage is not uniformly required. This means your coverage and cost depend on the specific medication and your specific plan. Generally, Medicare Part D or a Medicare Advantage Prescription Drug (MAPD) plan provides drug coverage for Medicare, including for covered inhalers. However, if you need to use the drug with a nebulizer, your coverage would fall under Part B.
Globe and Mail
13 hours ago
- Health
- Globe and Mail
Novo Nordisk Stock (NVO) Inches Higher Despite More U.K. Weight Jab Concerns
Shares in pharmaceutical giant Novo Nordisk (NVO) edged higher today despite more pressure from health officials in the U.K. about the safety of weight-loss drugs. Confident Investing Starts Here: Pancreas Link The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) said today that it will investigate whether there is a link between weight-loss injections and acute inflammation of the pancreas. Indeed, they are asking people on weight-loss drugs who have been hospitalized by acute pancreatitis to get in touch. This comes after data from MHRA which showed that since the drugs were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking GLP-1 medicines. That includes 113 cases and one death linked to semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic weight-loss injections. Meanwhile, 181 cases, with five deaths, were reported linked to tirzepatide, which is the active ingredient in Eli Lilly's (LLY) rival Mounjaro treatment. MHRA chief safety officer Dr Alison Cave said the aim was to 'better predict those most at risk of adverse reactions.' Think Twice This follows a warning earlier this month from the MHRA to pregnant women that it is unclear whether weight-loss injections could harm unborn babies. Russ Mould, investment director at AJ Bell, said this regular commentary on the side effects of injectable weight-loss drugs could make some patients think twice about using them. 'Reports of pancreas-related illnesses in a tiny number of cases could yet attract regulatory scrutiny,' he added. In the UK, the injections are only available through the state-run National Health Service, but people are still accessing them via sellers on social media or beauty salons. The demand is expected to be there. Globally, about 3.8 billion people over 25 and just under 750 million children and young people will be overweight or obese by 2050. Is NVO a Good Stock to Buy Now? On TipRanks, NVO has a Moderate Buy consensus based on 4 Buy, 3 Hold and 1 Sell rating. Its highest price target is $142.56. NVO stock's consensus price target is $94.79 implying a 40.32% upside. See more NVO analyst ratings
